A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Summary

This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.

Timeline

Start

2021-09-09

Primary completion

2024-06-09

Completion

2025-08-15

Outcome

Met primary endpoint

release “HR19042胶囊治疗原发性IgA肾病患者的Ⅱ/Ⅲ期研究结果获选在高影响力临床试验（HIT! High Impact Clinical Trials）专场进行口头汇报 [1] 。结果显示， 本研究达到所有主要终点” hengrui.com ↗

Publications

• Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Indications